Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
- PMID: 15096915
- DOI: 10.1097/00008877-200403000-00007
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
Abstract
Relatively few studies have assessed the reinforcing effects of hallucinogenic compounds, and no such studies have attempted to engender contingent responding for these compounds in animals with behavioral histories that include experience with serotonergically mediated reinforcing effects. The objectives of the present study were to investigate the capacity of several hallucinogenic compounds to maintain self-administration behavior in rhesus monkeys with a previous history of 3,4-methylenedioxymethamphetamine (MDMA) self-administration, and to compare these effects across a range of doses of drugs from two structural classes (indolealkylamines and phenylisopropylamines). The results indicate that no compound generated reliable responding and that no subject ever self-administered 4-iodo-2,5-dimethoxyphenylisopropylamine (DOI) at rates above those engendered by contingent saline. However, 3 out of 4 subjects did respond at rates between 0.75 and 3.0 responses/s in one or more sessions where N,N-dimethyltryptamine (DMT), mescaline or psilocybin were available. During some of these sessions in which self-administration was maintained, animals earned a majority of all available infusions and appeared intoxicated by the end of the session. This pattern of transient self-administration may indicate that these compounds have weak reinforcing effects, or mixed reinforcing and aversive effects.
Copyright 2004 Lippincott Williams & Wilkins
Similar articles
-
A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys.Drug Alcohol Depend. 2005 May 9;78(2):135-40. doi: 10.1016/j.drugalcdep.2004.10.006. Epub 2004 Dec 8. Drug Alcohol Depend. 2005. PMID: 15845316
-
Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?Psychopharmacology (Berl). 2007 Jan;189(4):471-82. doi: 10.1007/s00213-006-0320-8. Epub 2006 Mar 23. Psychopharmacology (Berl). 2007. PMID: 16555062 Review.
-
Neurological aspects of hallucinogenic drugs.Adv Neurol. 1975;13:47-78. Adv Neurol. 1975. PMID: 814800 Review. No abstract available.
-
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement.Psychopharmacology (Berl). 2002 Jun;161(4):356-64. doi: 10.1007/s00213-002-1021-6. Epub 2002 Apr 19. Psychopharmacology (Berl). 2002. PMID: 12073162
-
Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys.Psychopharmacology (Berl). 2008 Jan;196(1):63-70. doi: 10.1007/s00213-007-0932-7. Epub 2007 Sep 27. Psychopharmacology (Berl). 2008. PMID: 17899019 Free PMC article.
Cited by
-
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.Front Pharmacol. 2023 Oct 11;14:1239159. doi: 10.3389/fphar.2023.1239159. eCollection 2023. Front Pharmacol. 2023. PMID: 37886127 Free PMC article. Review.
-
Serotonin 2C receptors are also important in head-twitch responses in male mice.Psychopharmacology (Berl). 2023 Oct 26. doi: 10.1007/s00213-023-06482-9. Online ahead of print. Psychopharmacology (Berl). 2023. PMID: 37882810
-
Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys.J Pharmacol Exp Ther. 2023 Jan;384(1):155-162. doi: 10.1124/jpet.122.001318. Epub 2022 Oct 22. J Pharmacol Exp Ther. 2023. PMID: 36272734 Free PMC article.
-
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS Drugs. 2022 Oct;36(10):1031-1047. doi: 10.1007/s40263-022-00944-y. Epub 2022 Sep 12. CNS Drugs. 2022. PMID: 36097251 Free PMC article.
-
Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.Psychopharmacology (Berl). 2022 Jun;239(6):1907-1932. doi: 10.1007/s00213-021-06049-6. Epub 2022 Jan 13. Psychopharmacology (Berl). 2022. PMID: 35022823 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources